专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140045215A1 NEUTRALIZING ANTI-CCL20 ANTIBODIES 有权
标题翻译：中性抗CCL20抗体
公开(公告)号：US20140045215A1
公开(公告)日：2014-02-13
申请号：US13924433
申请日：2013-06-21
申请人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
发明人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
IPC分类号： C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
摘要： The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
摘要翻译：本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。本发明还涉及所述抗体的重链和轻链。本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。

2. 发明授权

US08491901B2 Neutralizing anti-CCL20 antibodies 有权
标题翻译：中和抗CCL20抗体
公开(公告)号：US08491901B2
公开(公告)日：2013-07-23
申请号：US13300352
申请日：2011-11-18
申请人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
发明人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
摘要： The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
摘要翻译：本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。本发明还涉及所述抗体的重链和轻链。本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。

3. 发明申请

US20120148592A1 NEUTRALIZING ANTI-CCL20 ANTIBODIES 有权
标题翻译：中性抗CCL20抗体
公开(公告)号：US20120148592A1
公开(公告)日：2012-06-14
申请号：US13300352
申请日：2011-11-18
申请人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
发明人： Toshio Imai , Brad Kline , Tetsu Kawano , Luigi Grasso , Yoshimasa Sakamoto , Jared Spidel , Miyuki Nishimura , Kenzo Muramoto , Tatsuo Horizoe
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , C12P21/08 , C12N5/071 , A61P35/00 , A61P29/00 , A61P19/02 , A61P31/20 , A61P19/10 , C12N1/21 , C12N1/15 , C12N1/19 , C12N5/10 , C07K16/18
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92 , G01N33/6863 , G01N2333/521
摘要： The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
摘要翻译：本发明涉及对人CC趋化因子配体20（CCL20）具有结合特异性的新型人源化，嵌合和鼠抗体。本发明还涉及所述抗体的重链和轻链。本发明还涉及分离的核酸，重组载体和宿主细胞，其包含编码所述抗体的重链和/或轻链的序列，以及制备所述抗体的方法。本发明的抗CCL20抗体可用于治疗例如炎性和自身免疫性疾病和癌症的治疗应用。

4. 发明申请

US20080132507A1 Hydrazide Derivatives 审中-公开
标题翻译：酰肼衍生物
公开(公告)号：US20080132507A1
公开(公告)日：2008-06-05
申请号：US11665385
申请日：2005-10-13
申请人： Richard Clark , Shinsuke Hirota , Hiroshi Azuma , Kazunobu Kira , Nobuhisa Watanabe , Tadashi Nagakura , Tatsuo Horizoe
发明人： Richard Clark , Shinsuke Hirota , Hiroshi Azuma , Kazunobu Kira , Nobuhisa Watanabe , Tadashi Nagakura , Tatsuo Horizoe
IPC分类号： A61K31/5375 , C07D213/02 , C07D239/24 , C07D333/02 , C07D307/02 , C07D215/00 , C07D295/00 , C07D249/04 , C07D241/10 , A61P9/10 , A61P11/00 , A61K31/4965 , A61K31/50 , A61K31/4192 , C07C63/00 , C07C57/00 , A61K31/19 , A61K31/44 , A61K31/505 , A61K31/381 , A61K31/47
CPC分类号： C07D209/48 , C07C257/18 , C07C311/49 , C07C317/14 , C07C317/44 , C07C337/06 , C07D209/08 , C07D213/30 , C07D213/54 , C07D213/71 , C07D213/77 , C07D213/80 , C07D213/82 , C07D213/86 , C07D213/87 , C07D213/89 , C07D215/38 , C07D233/90 , C07D237/20 , C07D239/28 , C07D239/42 , C07D249/18 , C07D257/04 , C07D295/32 , C07D307/68 , C07D333/24 , C07D471/04
摘要： A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc., R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc., Z1, Z2 and Z3 each independently represent hydrogen, etc., Z4 represents hydrogen, etc. and X represents a single bond or —CO—, etc.
摘要翻译：由下列通式（1）表示的化合物或其盐或其水合物是安全的，同时具有合适的物理化学稳定性，并且可用作与血栓形成相关的疾病的治疗或预防剂。其中R 1a，R 1b，R 1c和R 1d各自独立地表示氢等， O 2表示任选取代的苯基等，R 3表示任选取代的C 6-10芳基等，Z 1，Z 2， Z 3和Z 3各自独立地表示氢等，Z 4表示氢等，X表示单键或-CO-等。

5. 发明授权

US07816522B2 Triazolone derivatives 有权
标题翻译：三唑酮衍生物
公开(公告)号：US07816522B2
公开(公告)日：2010-10-19
申请号：US11723893
申请日：2007-03-22
申请人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
发明人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
IPC分类号： A61K31/41 , A61K31/415 , C07D233/00 , C07D249/00
CPC分类号： C07D249/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D413/14 , C07D417/04
摘要： A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen]
摘要翻译：由以下通式（1）表示的化合物，其盐或其前体的水合物是可用于治疗和/或预防与血栓形成有关的疾病的新型化合物，其具有合适的理化稳定性更安全。 [其中R1a，R1b，R1c和R1d各自独立地表示氢等; R2代表任选取代的苯基等; R3代表任选取代的C6-10芳基等; 并且Z 1和Z 2各自独立地表示氢]

6. 发明申请

US20060177444A1 Concomitant drug as therapeutic agent for inflammatory bowel disease 审中-公开
标题翻译：伴随药物作为炎症性肠病的治疗剂
公开(公告)号：US20060177444A1
公开(公告)日：2006-08-10
申请号：US10549321
申请日：2004-03-18
申请人： Tatsuo Horizoe
发明人： Tatsuo Horizoe
IPC分类号： A61K38/22 , A61K39/395 , A61K31/60 , A61K31/573 , A61K31/198
CPC分类号： C07K16/241 , A61K31/00 , A61K38/13 , A61K45/06 , A61K2300/00
摘要： An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.
摘要翻译：本发明的目的是提供一种对炎症性肠病如溃疡性结肠炎或克罗恩病有效的药物。具体地说，本发明提供了一种炎症性肠病治疗剂，其含有由至少一种具有炎性抑制活性的化合物组成的活性成分（a），所述化合物具有选自氨基水杨酸衍生物，抗炎性糖皮质激素，免疫抑制化合物，抗TNFα 与由至少一种具有PPARγ激动活性的化合物组成的活性成分（b）组合，其中所述试剂配置成使得化合物（a）和化合物（b）同时使用，分别或每个预定的时间。

7. 发明授权

US06841549B1 Condensed imidazole compounds and a therapeutic agent for diabetes mellitus 失效
标题翻译：缩合咪唑化合物和糖尿病治疗剂
公开(公告)号：US06841549B1
公开(公告)日：2005-01-11
申请号：US10018688
申请日：2000-06-30
申请人： Osamu Asano , Hitoshi Harada , Seiji Yoshikawa , Nobuhisa Watanabe , Takashi Inoue , Tatsuo Horizoe , Nobuyuki Yasuda , Kaya Ohashi , Hiroe Minami , Junsaku Nagaoka , Manabu Murakami , Seiichi Kobayashi , Isao Tanaka , Tsutomu Kawata , Naoyuki Shimomura , Hiroshi Akamatsu , Naoki Ozeki , Toshikazu Shimizu , Kenji Hayashi , Toyokazu Haga , Shigeto Negi , Toshihiko Naito
发明人： Osamu Asano , Hitoshi Harada , Seiji Yoshikawa , Nobuhisa Watanabe , Takashi Inoue , Tatsuo Horizoe , Nobuyuki Yasuda , Kaya Ohashi , Hiroe Minami , Junsaku Nagaoka , Manabu Murakami , Seiichi Kobayashi , Isao Tanaka , Tsutomu Kawata , Naoyuki Shimomura , Hiroshi Akamatsu , Naoki Ozeki , Toshikazu Shimizu , Kenji Hayashi , Toyokazu Haga , Shigeto Negi , Toshihiko Naito
IPC分类号： A61P3/10 , A61P43/00 , C07D471/04 , C07D473/00 , C07D473/34 , C07D473/40 , A16K31/33 , C07D239/70 , C07D471/00 , C07D487/00 , A16K31/52
CPC分类号： C07D471/04 , C07D473/00 , C07D473/34 , C07D473/40
摘要： The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.
摘要翻译：本发明提供了一种基于腺苷A2受体拮抗剂作用的新型糖尿病和糖尿病并发症的预防或治疗剂。即提供了具有腺苷A2受体拮抗剂作用的新颖的缩合咪唑化合物，是有效预防或治疗糖尿病和糖尿病并发症，并由式（I）表示;（其中R 1表示例如可被烷基取代的氨基; R 2表示例如氢原子，可以被羟基取代的烷基，环烷基或烷基，烯基或炔基; R 3表示例如任选取代的烷基，烯基，炔基，芳基，杂芳基，吡啶酮基，嘧啶酮基或哌嗪酮基; Ar表示例如任选取代的芳基或杂芳基; Q和W彼此相同或不同，每个代表 N或CH），其药理学上可接受的盐或其水合物。

8. 发明申请

US20110112109A1 TRIAZOLONE DERIVATIVES 有权
标题翻译：三唑酮衍生物
公开(公告)号：US20110112109A1
公开(公告)日：2011-05-12
申请号：US13006004
申请日：2011-01-13
申请人： Richard CLARK , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
发明人： Richard CLARK , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
IPC分类号： A61K31/501 , A61K31/4196 , A61K31/506 , A61K31/4439 , A61K31/497 , A61K31/427 , A61K31/4245 , A61P7/02
CPC分类号： C07D249/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D413/14 , C07D417/04
摘要： A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.
摘要翻译：由下列通式（1）表示的化合物或其盐或上述的水合物：其中R1a，R1b，R1c和R1d各自独立地表示氢等; R2代表任选取代的苯基等; R3代表任选取代的C6-10芳基等; Z1和Z2各自独立地表示氢。

9. 发明申请

US20080015199A1 Triazolone derivatives 有权
标题翻译：三唑酮衍生物
公开(公告)号：US20080015199A1
公开(公告)日：2008-01-17
申请号：US11723893
申请日：2007-03-22
申请人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
发明人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
IPC分类号： A61K31/4196 , A61K31/427 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61P7/02 , A61P9/00 , C07D249/08 , C07D401/04 , C07D403/04 , C07D409/04 , C07D417/04
CPC分类号： C07D249/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D413/14 , C07D417/04
摘要： A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen]
摘要翻译：由以下通式（1）表示的化合物，其盐或其前体的水合物是可用于治疗和/或预防与血栓形成有关的疾病的新型化合物，其具有合适的理化稳定性更安全。 [其中R 1a，R 1b，R 1c和R 1d各自独立地表示氢等。 R 2表示任选取代的苯基等; R 3表示任选取代的C 6-10芳基等; Z 1和Z 2各自独立地表示氢]

10. 发明授权

US08163787B2 Triazolone derivatives 有权
标题翻译：三唑酮衍生物
公开(公告)号：US08163787B2
公开(公告)日：2012-04-24
申请号：US13006004
申请日：2011-01-13
申请人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
发明人： Richard Clark , Fumiyoshi Matsuura , Kazunobu Kira , Shinsuke Hirota , Hiroshi Azuma , Tadashi Nagakura , Tatsuo Horizoe , Kimiyo Tabata , Kazutomi Kusano , Takao Omae , Atsushi Inoue
IPC分类号： A61K31/41 , A61K31/415 , C07D233/00 , C07D249/00
CPC分类号： C07D249/12 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D413/14 , C07D417/04
摘要： A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.
摘要翻译：由下列通式（1）表示的化合物或其盐或前述的水合物：其中R1a，R1b，R1c和R1d各自独立地表示氢等; R2代表任选取代的苯基等; R3代表任选取代的C6-10芳基等; Z1和Z2各自独立地表示氢。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式